<DOC>
	<DOCNO>NCT00056030</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Monoclonal antibody cetuximab locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Combining chemotherapy cetuximab may kill tumor cell . PURPOSE : This phase II trial study well give combination chemotherapy together cetuximab work treat patient unresectable liver metastasis colorectal cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Cetuximab Treating Patients With Liver Metastases From Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine surgical resectability rate patient unresectable hepatic metastasis secondary metastatic colorectal adenocarcinoma treat oxaliplatin , fluorouracil , leucovorin calcium , cetuximab . - Determine response rate overall survival patient treat regimen . - Determine quality life patient treat regimen . - Determine toxicity regimen patient . OUTLINE : This multicenter study . Patients receive cetuximab IV 1 hour ( 2 hour day 1 course 1 ) day 1 8 . Patients also receive oxaliplatin IV 2 hour leucovorin calcium IV 2 hour day 1 fluorouracil IV continuously day 1-2 . Treatment repeat every 2 week absence disease progression unacceptable toxicity , minimum 12 course deem resectable disease . Quality life assess baseline prior treatment course . Patients follow every 3 month 1 year every 6 month 3 year . PROJECTED ACCRUAL : A total 67-73 patient accrue study within 4 year .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : History completely resect primary adenocarcinoma colon rectum No gross microscopic evidence residual disease Liver metastases , meet 1 follow criterion : Not optimally resectable Requires resection 3 major hepatic vein , portal vein bifurcation , retrohepatic vena cava Includes main right main leave portal vein main hepatic vein opposite lobe Requires right leave trisegmentectomy At least 6 metastatic lesion distribute diffusely lobes liver Measurable disease At least 1 measurable lesion ≥ 20 mm No evidence extrahepatic metastasis physical examination xray No previously resect extrahepatic metastasis PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 01 Life expectancy Not specify Hematopoietic Hemoglobin ≥ 9 g/dL Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic AST ≤ 3 time upper limit normal ( ULN ) Bilirubin ≤ ULN No preexist chronic hepatic disease ( e.g. , chronic active hepatitis , cirrhosis ) would preclude surgical resection metastases Renal Creatinine ≤ 1.5 time ULN Cardiovascular No myocardial infarction within past 6 month No clinical evidence congestive heart failure No New York Heart Association class IIIIV heart disease No significant cardiac disease No uncontrolled hypertension No unstable angina No congestive heart failure No uncontrolled arrhythmias Gastrointestinal Adequate oral nutrition estimate caloric intake ≥ 1,500 calories/day No severe anorexia frequent nausea and/or vomit No history gastrointestinal bleeding appropriately address Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Able tolerate major surgery No prior allergic reaction know sensitivity chimerized murine monoclonal antibody therapy No document presence human antimouse antibodies No known allergy platinum compound No malignancy within past 5 year except basal cell squamous cell skin cancer , carcinoma situ , tumor associate less 10 % probability death within 5 year diagnosis No preexist neuropathy ≥ grade 2 No symptomatic pulmonary fibrosis interstitial pneumonitis No uncontrolled bacterial viral infection HIV negative No fungal infection PRIOR CONCURRENT THERAPY : Biologic therapy No colonystimulating factor within 24 hour day 1 course No concurrent immunotherapy Chemotherapy At least 1 year since prior adjuvant systemic fluorouracil without levamisole without leucovorin calcium No prior oxaliplatin No prior systemic chemotherapy metastatic disease No prior chemoembolization metastatic disease No prior hepatic artery infusion chemotherapy metastatic disease No concurrent chemotherapy Endocrine therapy Not specify Radiotherapy At least 12 month since prior adjuvant radiotherapy Prior radiofrequency ablation allow No prior radiotherapy liver No prior radiotherapy 25 % bone marrow No concurrent radiotherapy Surgery See Disease Characteristics More 21 day since prior abdominal exploration ( without intestinal resection ) Other No prior antiEGFRdirected therapy Prior cryotherapy allow No oral cryotherapy day 1 course</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>liver metastasis</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma rectum</keyword>
</DOC>